These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32319167)

  • 1. Real world evidence on treatment of chronic spontaneous urticaria with omalizumab: Preliminary data.
    Corrao S; Prestigiacomo MA; Angileri RG; Natoli G; Argano C
    Dermatol Ther; 2020 Jul; 33(4):e13458. PubMed ID: 32319167
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
    Exposito-Serrano V; Curto-Barredo L; Aguilera Peiro P; Gómez Armayones S; Serra-Baldrich E; Spertino J; Bonfill Ortí M; Figueras Nart I; Melé-Ninot G; Baliu-Piqué C; Sala Cunill A; Labrador-Horrillo M; Guilabert Vidal A; Fernández Chico N; Giménez-Arnau AM
    Br J Dermatol; 2021 Jan; 184(1):167-168. PubMed ID: 32730636
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study.
    Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C
    J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic spontaneous urticaria refractory to cyclosporine add-on omalizumab successfully treated with methotrexate add-on.
    Garbayo-Salmons P; Expósito-Serrano V
    Dermatol Ther; 2020 Nov; 33(6):e14469. PubMed ID: 33112010
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.
    Passante M; Napolitano M; Dastoli S; Bennardo L; Fabbrocini G; Nisticò SP; Patruno C
    Dermatol Ther; 2021 Nov; 34(6):e15111. PubMed ID: 34427028
    [No Abstract]   [Full Text] [Related]  

  • 8. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
    Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
    Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
    [No Abstract]   [Full Text] [Related]  

  • 10. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
    Karstarli Bakay OS; Kacar N
    Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
    Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
    Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals.
    Almeida LR; Criado RF; Criado PR; Ensina LF; Abdalla BMZ; Quaresma JAS
    An Bras Dermatol; 2021; 96(4):497-499. PubMed ID: 34001398
    [No Abstract]   [Full Text] [Related]  

  • 14. Validation of UAS7 among children with chronic spontaneous urticaria.
    Gabrielli S; Mulé P; Prosty C; Gooding G; Le M; Zhang L; Netchiporouk E; Baum S; Greenberger S; Ensina LF; Lovett A; Zhang X; Ben-Shoshan M
    J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1927-1929.e1. PubMed ID: 35272072
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term follow-up effect of omalizumab in chronic spontaneous urticaria and its association with serum C-reactive protein levels.
    Baysak S; Sevim Kecici A; Dogan B
    Dermatol Ther; 2020 Jul; 33(4):e13663. PubMed ID: 32447802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study.
    Song XT; Chen YD; Yu M; Liu B; Zhao ZT; Maurer M
    Allergy; 2021 Apr; 76(4):1271-1273. PubMed ID: 33275779
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
    Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
    Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
    [No Abstract]   [Full Text] [Related]  

  • 18. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896
    [No Abstract]   [Full Text] [Related]  

  • 19. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose omalizumab use in patients with chronic spontaneous urticaria.
    Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.